Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.

Christopher Parker,Fei Fei Liu,Kristen A Deger,Conrado Franco-Villalobos,Irina Proskorovsky,Scott J Keating,Sonja Sorensen

Advances in therapy（2023）

引用 0|浏览14

暂无评分

摘要

This analysis estimated that liso-cel is cost-effective compared with tisa-cel and axi-cel from a commercial US payer perspective.

查看译文

关键词

Axicabtagene ciloleucel,Chimeric antigen receptor,Cost-effectiveness,Large B-cell lymphoma,Lisocabtagene maraleucel,Non-Hodgkin lymphoma,Quality-adjusted life-year,Tisagenlecleucel

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要